These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 35012577)
1. Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation. Dumesic DA; Padmanabhan V; Chazenbalk GD; Abbott DH Reprod Biol Endocrinol; 2022 Jan; 20(1):12. PubMed ID: 35012577 [TBL] [Abstract][Full Text] [Related]
2. An Evolutionary Model for the Ancient Origins of Polycystic Ovary Syndrome. Dumesic DA; Abbott DH; Chazenbalk GD J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834765 [TBL] [Abstract][Full Text] [Related]
10. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Tehrani FR; Rashidi H; Khomami MB; Tohidi M; Azizi F Reprod Biol Endocrinol; 2014 Sep; 12():89. PubMed ID: 25224635 [TBL] [Abstract][Full Text] [Related]
12. The impact of obesity on reproduction in women with polycystic ovary syndrome. Pasquali R; Gambineri A; Pagotto U BJOG; 2006 Oct; 113(10):1148-59. PubMed ID: 16827825 [TBL] [Abstract][Full Text] [Related]
13. Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys. Abbott DH; Rayome BH; Dumesic DA; Lewis KC; Edwards AK; Wallen K; Wilson ME; Appt SE; Levine JE Hum Reprod; 2017 Apr; 32(4):923-936. PubMed ID: 28333238 [TBL] [Abstract][Full Text] [Related]
14. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Möhlig M; Weickert MO; Ghadamgadai E; Machlitt A; Pfüller B; Arafat AM; Pfeiffer AF; Schöfl C Eur J Endocrinol; 2007 Aug; 157(2):195-200. PubMed ID: 17656598 [TBL] [Abstract][Full Text] [Related]
16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ; Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855 [TBL] [Abstract][Full Text] [Related]
17. Is foetal hyperexposure to androgens a cause of PCOS? Filippou P; Homburg R Hum Reprod Update; 2017 Jul; 23(4):421-432. PubMed ID: 28531286 [TBL] [Abstract][Full Text] [Related]
18. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index. Condorelli RA; Calogero AE; Di Mauro M; Mongioi' LM; Cannarella R; Rosta G; La Vignera S J Endocrinol Invest; 2018 Apr; 41(4):383-388. PubMed ID: 28942551 [TBL] [Abstract][Full Text] [Related]
19. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism. Ezeh U; Ezeh C; Pisarska MD; Azziz R Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559 [TBL] [Abstract][Full Text] [Related]
20. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Zheng SH; Li XL Gynecol Endocrinol; 2016; 32(3):177-83. PubMed ID: 26502288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]